高い4本鎖DNA結合特異性を有する新規化合物の抗腫瘍効果と有害作用の検討

Telomerase which extends telomere sequences to the end of chromosome is overexpressed in more than 80% of cancer cells, thus it is expected as a target for developing anticancer drug. As the telomeric repeat sequences form characteristic quadruplex DNA structure, we here investigated the effects of...

Full description

Saved in:
Bibliographic Details
Published in日本薬理学会年会要旨集 p. 2-P-225
Main Authors 土生, 学, 福田, 晃, 佐藤, しのぶ, 笹栗, 正明, 東, 泉, 冨永, 和宏, 大住, 伴子, 竹中, 繁織, 竹内, 弘
Format Journal Article
LanguageJapanese
Published 公益社団法人 日本薬理学会 2020
Subjects
Online AccessGet full text
ISSN2435-4953
DOI10.1254/jpssuppl.93.0_2-P-225

Cover

More Information
Summary:Telomerase which extends telomere sequences to the end of chromosome is overexpressed in more than 80% of cancer cells, thus it is expected as a target for developing anticancer drug. As the telomeric repeat sequences form characteristic quadruplex DNA structure, we here investigated the effects of novel compounds with improved binding specificity to quadruplex DNA structure, namely, cyclic naphthalene diimide (cNDI) and cyclic anthraquinone (cAQ), on various cultured cells.Human cancer cell line Ca9-22, SAS, HSC-2, HeLa, and human normal keratinocytes, mouse bone marrow cells were used in this study. Cell proliferation was examined by WST-8 assay and direct counting using a hemocytometer. Gene expression was analyzed by general PCR and real-time PCR using reverse transcribed total RNA prepared from the cells.All the derivatives of cNDI and cAQ inhibited cell growth in a dose-dependent manner, and the effect of some compounds tended to correlate with the mRNA expression level of TERT gene. Furthermore, the novel compounds showed a strong cell growth inhibitory effect against cancer-derived cell lines by comparing mouse bone marrow cells with human normal epidermal keratinocytes. The results suggested that cNDI and cAQ derivatives are considered to be promising as new anticancer agents with improved cancer specificity.
Bibliography:93_2-P-225
ISSN:2435-4953
DOI:10.1254/jpssuppl.93.0_2-P-225